Sunitinib (SU011248) (Sutent; Pfizer Inc, New York, New York) is an oral multikinase phosphorylation inhibitor of receptor tyrosine kinases (RTKs), which are implicated in tumor growth, angiogenesis, and metastasis of cancer. Although it is approved for use in the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma, sunitinib has also been shown to be efficacious in treating neuroendocrine, colon, and breast cancers.1 Dermatologic adverse effects include rash, skin discoloration, hair color changes, xerosis, alopecia, and seborrheic dermatitis–like reactions.2 Palmoplantar erythrodysesthesia (PPE) was reported in 12% to 14% of patients in large phase 2 and 3 studies.3 To our knowledge, we describe herein the first case of sunitinib-related intense periungual erythema and severe mucositis in addition to bullous PPE.
Suwattee P, Chow S, Berg BC, Warshaw EM. Sunitinib: A Cause of Bullous Palmoplantar Erythrodysesthesia, Periungual Erythema, and Mucositis. Arch Dermatol. 2008;144(1):123–125. doi:10.1001/archderm.144.1.123
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: